BREZ nears YD Biopharma merger with $13.2M PIPE but faces cash, warrant and going‑concern risks

Breeze Holdings Acquisition Corp. (NASDAQ: BREZ)

Quick take: BREZ is a SPAC in the late stages of a business combination with YD Biopharma (Pubco). The deal received shareholder approval (special meeting Aug 14, 2025) and a $13.2M PIPE commitment, but the company runs low on operating cash, carries large warrant liabilities and reports a going-concern qualification.

Key facts & statistics

- Cash held in Trust Account: $2,759,408 (June 30, 2025)

- Cash outside Trust Account: $6,312 (June 30, 2025)

- Total assets: $2,951,490; Total liabilities: $19,001,855 (June 30, 2025)

- Warrant liabilities: $7,785,500 (June 30, 2025)

- Due to Sponsor / related-party obligations: $10,390,465 (June 30, 2025)

- Accumulated deficit: $(18,710,088) (June 30, 2025)

- Common shares outstanding: 3,140,000 (issued/outstanding at June 30, 2025); 3,314,698 reported outstanding as of Aug 19, 2025 after subsequent redemptions

- Working capital deficit (excluding certain receivables/payables): $10,824,317 (June 30, 2025)

- Three months ended June 30, 2025: Net loss $2,214,684; operating costs $389,191; change in fair value of warrants (loss) $1,861,750; basic/diluted net loss per share $0.65

- Six months ended June 30, 2025: Net loss $5,582,198; operating costs $743,010; change in fair value of warrants (loss) $4,908,250; basic/diluted net loss per share $1.63

- Public Warrant quoted price used as proxy: $0.46 per warrant (June 30, 2025)

- PIPE commitment to Pubco (concurrent with closing): $13.2 million (subscription agreements for 1,650,000 shares at $8.00)

What's happening inside the company (plain)

- BREZ remains a blank‑check company that has not generated operating revenue; all activity is directed to completing a business combination.

- Management executed multiple one‑month extensions and accepted sponsor loans to buy time; sponsor loans and extension deposits total materially to support operations but create a large related‑party payable.

- The company remeasures its warrant liabilities each period; those remeasurements drove large non‑operating swings (gains in 2024, losses in 2025) and are the primary driver of reported net loss in the periods shown.

- The merger with YD Biopharma advanced: Merger Agreement amended (May 30, 2025), PIPE commitments secured ($13.2M), and shareholders approved the business combination at a special meeting (Aug 14, 2025). Redemptions and extension deposits continued through August 2025.

Positive aspects

- Trust account still holds cash ($2.76M) earmarked for a transaction and interest; PIPE commitments of $13.2M provide conditional financing for the closing.

- Sponsor has continued to fund working capital and extensions (non‑interest promissory notes), demonstrating sponsor support to keep the SPAC alive until closing.

- Business combination received shareholder approval (Aug 14, 2025) - critical procedural milestone toward closing.

Negative aspects (income statement & financial health)

- Operating cash outside the trust is essentially exhausted ($6,312) and the company reports a significant working capital deficit and a formal going‑concern assessment - management admits substantial doubt about continuing operations without the business combination or additional funding.

- Large and volatile non‑operating losses from remeasurement of warrant liabilities (loss of $4.91M for six months) dominate reported results; these are accounting movements that can swing reported profit/loss materially and unpredictably.

- Total liabilities ($19.0M) exceed total assets by a wide margin; related‑party payables to Sponsor ($10.39M) are sizeable and repayable on closing or maturity, increasing financial leverage and risk.

- Prior delisting from Nasdaq and transfer to OTC markets (May-Aug 2024 / Mar-Jun 2025 activity) reduced liquidity and public market visibility.

- Management disclosed material weaknesses in internal controls related to tax accounting and warrant valuation processes - increases execution and reporting risk.

Near‑term catalysts & watch items

- Closing of the business combination with YD Biopharma (Pubco) and receipt of PIPE proceeds - will determine whether the company emerges as an operating public company or must liquidate.

- Final settlement of sponsor loans and whether sponsor converts, is repaid, or remains as ongoing liability.

- Warrant valuation and market price of warrants/stock after the combination - continued remeasurements will continue to move net income/(loss) until settlement or equity reclassification.

Bottom line: BREZ is one step from completing a transformational business combination with conditional PIPE support, but the company remains thin on operating cash, carries large warrant liabilities and related‑party debt, and has material control issues. The transaction closing (and PIPE funding) is the single biggest determinant of shareholder outcome - until then the company faces elevated financial and execution risk.